1.	Phase IV Randomized Study of Doxorubicin Hydrochloride Liposome Versus Capecitabine as First-Line Chemotherapy in Women With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
2.	A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO# 08-1373, NCT00900744
3.	Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-09-14B, NCT00984269
4.	A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114271, NCT01328054
5.	Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: A11-3691, NCT01537029
6.	A Study of PD-0332991 + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A5481008, NCT01740427
7.	Phase III Randomized Study of Letrozole With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF30008, UCLA-0311034-01, NCT00073528
8.	Breast Cancer Trial of an Investigational Drug versus Capecitabine in Male or Female Patients with Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XRP9881B/3001, NCT00081796
9.	Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446E2352, NCT00320710
10.	A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR005143, EPOANE3010, 2005-001817-17, NCT00338286
11.	Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000499633, NCCTG-N0574, ACOSOG-N0574, N0574, NCT00377156
12.	Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 112515, NCT00968968
13.	A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 114299, NCT01160211
14.	Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 102-00-301, NCT01204801
15.	Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000688097, ECOG-E2108, E2108, NCT01242800
16.	Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12444, 2010-018501-10, NCT01234337
17.	A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4997g, BO25734, 2011-000509-29, NCT01419197
18.	The BEACON Study (Breast Cancer Outcomes With NKTR-102) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11-PIR-11, NCT01492101
19.	A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CR100797, 212082PCR3010, 2011-005243-28, NCT01517802
20.	A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: D699BC00001, NCT01602380
21.	Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120F2302, 2011-005524-17, NCT01610284
22.	A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120F2303, 2012-002571-34, NCT01633060
23.	Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GO25632, 2011-005335-97, NCT01663727
24.	A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PUMA-NER-1301, 2012-004492-38, NCT01808573
25.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161